Table 2 CML treatment restrictions, negative medication experiences, and overall disease burden, according to current CML treatment
Imatinib | Dasatinib | Nilotinib | Imatinib vs. Dasatinib | Imatinib vs. Nilotinib | Dasatinib vs. Nilotinib | ||||
|---|---|---|---|---|---|---|---|---|---|
(N=208) | (N=38) | (N=49) | |||||||
N | % | N | % | N | % | p-value | p-value | p-value | |
Treatment Restrictions | |||||||||
Dietary Restrictions | |||||||||
While fasting | 5 | 2.40% | 0 | 0.00% | 42 | 85.71% | 0.33 | <.01 | <.01 |
With food | 146 | 70.19% | 14 | 36.84% | 2 | 4.08% | <.01 | <.01 | <.01 |
Without certain foods | 88 | 42.31% | 16 | 42.11% | 36 | 73.47% | 0.98 | <.01 | <.01 |
With water | 131 | 62.98% | 15 | 39.47% | 32 | 65.31% | <.01 | 0.76 | 0.02 |
Dissolve tablets in water and drink immediately | 3 | 1.44% | 0 | 0.00% | 1 | 2.04% | 0.46 | 0.76 | 0.38 |
Without other non-CML medications | 22 | 10.58% | 2 | 5.26% | 9 | 18.37% | 0.31 | 0.13 | 0.07 |
Dosing Requirements | |||||||||
Once each day | 105 | 50.48% | 17 | 44.74% | 3 | 6.12% | 0.52 | <.01 | <.01 |
Twice each day | 15 | 7.21% | 5 | 13.16% | 32 | 65.31% | 0.22 | <.01 | <.01 |
Two or more pills at one time | 26 | 12.50% | 3 | 7.89% | 24 | 48.98% | 0.42 | <.01 | <.01 |
At specific times of the day | 101 | 48.56% | 19 | 50.00% | 31 | 63.27% | 0.87 | 0.06 | 0.22 |
At specific hours apart | 32 | 15.38% | 7 | 18.42% | 38 | 77.55% | 0.64 | <.01 | <.01 |
Mean | SD | Mean | SD | Mean | SD | p-value | p-value | p-value | |
Treatment Restriction Score | −0.06 | 0.69 | −0.31 | 0.77 | 0.61 | 0.68 | 0.06 | <.01 | <.01 |
No. Treatment Doses (times per day) | 1.20 | 0.50 | 1.32 | 0.62 | 1.88 | 0.39 | 0.27 | <.01 | <.01 |
Negative Medication Experience | |||||||||
Experienced Score | 0.06 | 0.90 | −0.10 | 0.98 | 0.07 | 0.91 | 0.35 | 0.96 | 0.42 |
Bothersome Score | 0.02 | 0.70 | 0.10 | 0.62 | 0.07 | 0.74 | 0.47 | 0.66 | 0.83 |
Impact Score | 0.02 | 0.66 | 0.10 | 0.57 | 0.11 | 0.65 | 0.45 | 0.38 | 0.93 |
No. Non-CML Medications per day | 2.02 | 2.67 | 2.47 | 4.07 | 2.27 | 2.77 | 0.52 | 0.58 | 0.79 |
Time since CML diagnosis (years) | 4.85 | 4.31 | 5.32 | 4.47 | 3.69 | 4.14 | 0.55 | 0.09 | 0.09 |
Time on Current CML Treatment (years) | 4.60 | 2.98 | 2.07 | 1.69 | 1.55 | 1.35 | <.01 | <.01 | 0.12 |
No. Comorbidities | 1.17 | 2.13 | 1.97 | 3.19 | 1.59 | 2.71 | 0.14 | 0.32 | 0.56 |